Aptevo reports 93% clinical benefit rate with mipletamig triplet
Aptevo Therapeutics said mipletamig triplet produced a 93% clinical benefit rate in difficult-to-treat TP53-mutated frontline AML, with remission results described as nearly doubling published ven/aza outcomes.
Aptevo Therapeutics Inc. said remission results with mipletamig in a triplet regimen were nearly double published ven/aza outcomes in patients with historically limited treatment success. The Seattle-based clinical-stage biotechnology company, which develops novel multispecific immuno-oncology therapeutics, dated the update September 3, 2026.